Where Device VCs Have Gone Before
This article was originally published in Start Up
A deep dive of the portfolios of nearly three dozen device VCs shows that they’ve invested in certain therapeutic categories in the past including ophthalmic, cardiovascular, metabolic disease and spine. Like digging through soil to determine the climate conditions of eons past, the totals tell more about where the VC industry has been rather than where it’s going. But the past is sometimes of good indicator of what’s to come in both life and venture capital.
You may also be interested in...
In joint complaint, the FTC and New York Attorney General allege scheme to block generic Daraprim and maintain exorbitant list price; they cite hundreds of emails the incarcerated Shkreli has exchanged with co-defendant in last six months.
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.